Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Gentian Diagnostics ASA ( (DE:6FK) ) has shared an announcement.
Gentian Diagnostics ASA has signed an exclusive cooperation agreement with a leading global diagnostics company to develop a novel assay for integration on one of the world’s most widely used clinical chemistry analyser platforms, with Gentian handling both development and eventual manufacturing. The project is already well advanced, targeting a commercial launch in the second half of 2027, and will benefit from the partner’s global sales and distribution network, significantly expanding Gentian’s international market reach and reinforcing its positioning as a trusted partner for scalable, high-quality diagnostic solutions and long-term, partnership-driven growth in the global diagnostics market.
More about Gentian Diagnostics ASA
Gentian Diagnostics ASA is a Norwegian developer and manufacturer of high-quality in vitro diagnostic reagents, specialising in homogeneous immunoassays for conditions such as infections, inflammation, kidney failure and congestive heart failure. By converting clinically relevant biomarkers to automated, high-throughput analyser formats, the company serves global human and veterinary diagnostics markets from its headquarters in Moss with additional presence in Sweden, the USA and China.
Average Trading Volume: 12,631
Current Market Cap: NOK882.2M
For detailed information about 6FK stock, go to TipRanks’ Stock Analysis page.